Clinical Trials Logo

Acellular Pertussis clinical trials

View clinical trials related to Acellular Pertussis.

Filter by:

NCT ID: NCT01277705 Completed - Tetanus Clinical Trials

Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

Start date: January 2002
Phase: Phase 3
Study type: Interventional

This study will assess the immunogenicity and reactogenicity of the candidate GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine when administered to healthy subjects aged ≥ 15 years in Germany and ≥ 18 years in France compared to Boostrix™ and inactivated poliovirus vaccine administered separately, and with Revaxis®

NCT ID: NCT01248884 Completed - Hepatitis B Clinical Trials

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Start date: December 9, 2010
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety and immunogenicity of new formulations of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) when administered as a primary vaccination course to healthy infants at 2, 3 and 4 months of age.

NCT ID: NCT01245049 Completed - Tetanus Clinical Trials

Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children

Start date: April 1, 2011
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM Polio to that of Sanofi Pasteur MSD's RepevaxTM, when co-administered with a second dose of PriorixTM, in healthy 3 and 4-year-old children.

NCT ID: NCT01171989 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

Start date: August 18, 2010
Phase: Phase 2
Study type: Interventional

The current trial will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine when administered as a booster dose following priming in the first year of life with the same vaccine. This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00970307).

NCT ID: NCT01147900 Completed - Tetanus Clinical Trials

Evaluation of Boostrix™10 Years After Previous Booster Vaccination

Start date: June 15, 2010
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a dTpa (Boostrix™ vaccine) booster dose given 10 years after the previous vaccination with dTpa in GSK 263855/029 study. Only subjects who were part of the primary study will be invited to participate in this study.This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate study (see reference).

NCT ID: NCT01090453 Completed - Hepatitis B Clinical Trials

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Start date: May 17, 2010
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13® at 2, 4 and 12 months of age and with Rotarix™ at 2 and 4 months of age.

NCT ID: NCT01086423 Completed - Tetanus Clinical Trials

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Start date: March 1, 2010
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the immunogenicity and reactogenicity of Infanrix-IPV/Hib™ vaccine when administered to healthy Chinese infants at 2, 3 and 4 or 3, 4 and 5 months of age.

NCT ID: NCT00970307 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

Start date: August 13, 2009
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine co-administered with GSK Biologicals' 10-valent pneumococcal conjugate (GSK1024850A) vaccine given as a three-dose primary vaccination course at 2, 3 and 4 months of age.

NCT ID: NCT00964028 Completed - Tetanus Clinical Trials

Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

Start date: December 1, 2009
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and reactogenicity of Infanrix-IPV/Hib given as a three-dose primary vaccination course to healthy infants at 2-3-4 or 3-4-5 months of age.

NCT ID: NCT00908115 Completed - Tetanus Clinical Trials

Post Market Surveillance for Infanrix™

Start date: August 1, 2003
Phase:
Study type: Observational

The purpose of this study was to investigate the following questions through post-marketing surveillance: - Unknown/Unexpected adverse events and the serious adverse events. - The circumstances in which the adverse events occurred under the practical application. - Factors considered to have influence on safety. - Factors considered to have influence on efficacy. - Miscellaneous - Facts about mechanism, efficacy and safety which were not clearly known due to the inherent problems of the drugs.